Search

Your search keyword '"Hoare, Jonathan"' showing total 234 results
Start Over Author "Hoare, Jonathan"
234 results on '"Hoare, Jonathan"'

2. Device-assisted enteroscopy performance measures in the United Kingdom: DEEP-UK quality improvement project.

Author

Shiha, Mohamed G., Sidhu, Reena, Lucaciu, Laura A., Palmer-Jones, Christopher, Ayeboa-Sallah, Benjamin, Lazaridis, Nikolaos, Eckersley, Robert, Hiner, George E., Maxfield, Dominic, Shaheen, Walaa, Abduljabbar, Duaa, Hussain, Muhammad A., O'Hare, Rosie, Phull, Perminder S., Eccles, John, Caddy, Grant R., Butt, Mohammed A., Kurup, Arun, Chattree, Amit, and Hoare, Jonathan

Subjects
ENTEROSCOPY, CONSCIOUS sedation, ELECTRONIC records, SMALL intestine, ENDOSCOPY
Abstract

Background Device-assisted enteroscopy (DAE) has become a well-established diagnostic and therapeutic tool for the management of small-bowel pathology. We aimed to evaluate the performance measures for DAE across the UK against the quality benchmarks proposed by the European Society of Gastrointestinal Endoscopy (ESGE). Methods We retrospectively collected data on patient demographics and DAE performance measures from electronic endoscopy records of consecutive patients who underwent DAE for diagnostic and therapeutic purposes across 12 enteroscopy centers in the UK between January 2017 and December 2022. Results A total of 2005 DAE procedures were performed in 1663 patients (median age 60 years; 53% men). Almost all procedures (98.1%) were performed for appropriate indications. Double-balloon enteroscopy was used for most procedures (82.0%), followed by single-balloon enteroscopy (17.2%) and spiral enteroscopy (0.7%). The estimated depth of insertion was documented in 73.4% of procedures. The overall diagnostic yield was 70.0%. Therapeutic interventions were performed in 42.6% of procedures, with a success rate of 96.6%. Overall, 78.0% of detected lesions were marked with a tattoo. Patient comfort was significantly better with the use of deep sedation compared with conscious sedation (99.7% vs. 68.5%; P <0.001). Major adverse events occurred in only 0.6% of procedures. Conclusions Performance measures for DAE in the UK meet the ESGE quality benchmarks, with high diagnostic and therapeutic yields, and a low incidence of major adverse events. However, there is room for improvement in optimizing sedation practices, standardizing the depth of insertion documentation, and adopting marking techniques to aid in the follow-up of detected lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Device-assisted enteroscopy performance measures in the United Kingdom: DEEP-UK quality improvement project

Author

Despott, Edward J., primary, Sanders, David S., primary, Shiha, Mohamed G., additional, Sidhu, Reena, additional, Lucaciu, Laura A., additional, Palmer-Jones, Christopher, additional, Ayeboa-Sallah, Benjamin, additional, Lazaridis, Nikolaos, additional, Eckersley, Robert, additional, Hiner, George E., additional, Maxfield, Dominic, additional, Shaheen, Walaa, additional, Abduljabbar, Duaa, additional, Hussain, Muhammad A., additional, O’Hare, Rosie, additional, Phull, Perminder S., additional, Eccles, John, additional, Caddy, Grant R., additional, Butt, Mohammed A., additional, Kurup, Arun, additional, Chattree, Amit, additional, Hoare, Jonathan, additional, Jennings, Jason, additional, Longcroft-Wheaton, Gaius, additional, Collins, Paul, additional, Humphries, Adam, additional, and Murino, Alberto, additional

Published
2023
Full Text
View/download PDF

4. Imperialism & 'alternative' film culture : the Empire Marketing Board film unit : 1926-1933

Author

Hoare, Jonathan Giles

Subjects
791.43, Communication, cultural and media studies
Abstract

This thesis explores the early years of the British documentary movement as it formed within the Empire Marketing Board between 1926 and 1933. I begin by offering new insights into this formation by focusing on key institutions that have been under-researched in existing literature. The movement started with government money and resources, in a position formalised by the EMB's use of the Imperial Institute, a Victorian institution with an established history of public education, exhibition and research. Within this official institutional framework the EMB's filmmakers enjoyed an extraordinary level of creative freedom. They were simultaneously embedded within the'alternative' film culture that had developed from the independent screenings of the London Film Society (1925-1939). The Society offered coverage of the art and history of film for the first time in Britain, alongside showcasing a wealth of contemporaneous experimental and avant-Barde fiction and non-fiction work. Drawing on a variety of primary archival sources (some of which have not been previously explored) in the first three chapters I examine how the EMB's film unit developed in a relationship between the Board, the Imperial Institute and the Film Society. This position defined the work they produced, and the style and the content of their films for the EMB. The filmmakers were part of an Imperial discourse that aimed to promote Britain and the British Empire, however they were also engaging with, and contributing to, an international movement of filmmakers and intellectuals who were using documentary film to look closely at contemporary society from new perspectives. The fourth and fifth chapters offer fresh insights into filmmaking at the EMB, with a personal study based on new research into the life and work of Basil Wright. Although he was a central figure at the EMB, his role has remained under-researched. The material I present here offers a new account of the early formation of the documentary movement at the EMB and the original resources that the Board and its filmmakers drew upon.

Published
2010

5. CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype

Author

Thornhill, John P., Pace, Matthew, Martin, Genevieve E., Hoare, Jonathan, Peake, Simon, Herrera, Carolina, Phetsouphanh, Chan, Meyerowitz, Jodi, Hopkins, Emily, Brown, Helen, Dunn, Polly, Olejniczak, Natalia, Willberg, Christian, Klenerman, Paul, Goldin, Rob, Fox, Julie, Fidler, Sarah, Frater, John, and on behalf of the CHERUB investigators

Published
2019
Full Text
View/download PDF

6. Transcutaneous fluorescence spectroscopy as a tool for non-invasive monitoring of gut function: first clinical experiences

Author

Maurice, James, Lett, Aaron M., Skinner, Charlotte, Lim, Alexandra, Richardson, Matthew, Thomas, Ajesh Painadath, Summers, Peter A., Vyas, Khushi, Tadbier, Abdul Wadood, Vilar, Ramon, Kuimova, Marina K., Miodragovic, Serge, Vergis, Nikhil, Kelly, Paul, Cordeiro, Maria Francesca, Hoare, Jonathan, Darzi, Ara, Goldin, Robert, Thursz, Mark, and Thompson, Alex J.

Published
2020
Full Text
View/download PDF

8. Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry

Author

Tait, James, primary, Erridge, Simon, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Weatherall, Mark, additional, Rucker, James J, additional, Platt, Michael, additional, and Sodergren, Mikael H, additional

Published
2023
Full Text
View/download PDF

9. Data from De Novo Lipogenesis Alters the Phospholipidome of Esophageal Adenocarcinoma

Author

Abbassi-Ghadi, Nima, primary, Antonowicz, Stefan S., primary, McKenzie, James S., primary, Kumar, Sacheen, primary, Huang, Juzheng, primary, Jones, Emrys A., primary, Strittmatter, Nicole, primary, Petts, Gemma, primary, Kudo, Hiromi, primary, Court, Stephen, primary, Hoare, Jonathan M., primary, Veselkov, Kirill, primary, Goldin, Robert, primary, Takáts, Zoltán, primary, and Hanna, George B., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from De Novo Lipogenesis Alters the Phospholipidome of Esophageal Adenocarcinoma

Author

Abbassi-Ghadi, Nima, primary, Antonowicz, Stefan S., primary, McKenzie, James S., primary, Kumar, Sacheen, primary, Huang, Juzheng, primary, Jones, Emrys A., primary, Strittmatter, Nicole, primary, Petts, Gemma, primary, Kudo, Hiromi, primary, Court, Stephen, primary, Hoare, Jonathan M., primary, Veselkov, Kirill, primary, Goldin, Robert, primary, Takáts, Zoltán, primary, and Hanna, George B., primary

Published
2023
Full Text
View/download PDF

12. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry

Author

Olsson, Fabian, primary, Erridge, Simon, additional, Tait, James, additional, Holvey, Carl, additional, Coomber, Ross, additional, Beri, Sushil, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Weatherall, Mark W, additional, Platt, Michael, additional, Rucker, James J, additional, and Sodergren, Mikael H, additional

Published
2023
Full Text
View/download PDF

15. Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study

Author

Bapir, Lara, primary, Erridge, Simon, additional, Nicholas, Martha, additional, Pillai, Manaswini, additional, Dalavaye, Nishaanth, additional, Holvey, Carl, additional, Coomber, Ross, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Weatherall, Mark W, additional, Rucker, James J, additional, Platt, Michael, additional, and Sodergren, Mikael H, additional

Published
2023
Full Text
View/download PDF

18. Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy – Analysis from the UK Medical Cannabis Registry

Author

Erridge, Simon, additional, Holvey, Carl, additional, Coomber, Ross, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Platt, Michael W., additional, Rucker, James J., additional, Weatherall, Mark W., additional, Beri, Sushil, additional, and Sodergren, Mikael H., additional

Published
2022
Full Text
View/download PDF

19. A novel methodology for in vivo endoscopic phenotyping of colorectal cancer based on real-time analysis of the mucosal lipidome: a prospective observational study of the iKnife

Author

Alexander, James, Gildea, Louise, Balog, Julia, Speller, Abigail, McKenzie, James, Muirhead, Laura, Scott, Alasdair, Kontovounisios, Christos, Rasheed, Shanawaz, Teare, Julian, Hoare, Jonathan, Veselkov, Kirill, Goldin, Robert, Tekkis, Paris, Darzi, Ara, Nicholson, Jeremy, Kinross, James, and Takats, Zoltan

Published
2017
Full Text
View/download PDF

22. Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy—Analysis from the UK Medical Cannabis Registry.

Author

Erridge, Simon, Holvey, Carl, Coomber, Ross, Hoare, Jonathan, Khan, Shaheen, Platt, Michael W., Rucker, James J., Weatherall, Mark W., Beri, Sushil, and Sodergren, Mikael H.

Subjects
MEDICAL registries, MEDICAL marijuana, CANNABIDIOL, EPILEPSY, SEIZURES (Medicine)
Abstract

Background There is a paucity of high-quality evidence of the efficacy and safety of cannabis-based medicinal products in treatment of treatment-resistant epilepsy (TRE) in children. Methods A case series of children (<18 years old) with TRE from the UK Medical Cannabis Registry was analyzed. Primary outcomes were ≥50% reduction in seizure frequency, changes in the Impact of Pediatric Epilepsy Score (IPES), and incidence of adverse events. Results Thirty-five patients were included in the analysis. Patients were prescribed during their treatment with the following: CBD isolate oils (n = 19), CBD broad-spectrum oils (n = 17), and CBD/Δ9-THC combination therapy (n = 17). Twenty-three (65.7%) patients achieved a ≥50% reduction in seizure frequency. 94.1% (n = 16) of patients treated with CBD and Δ9-THC observed a ≥50% reduction in seizure frequency compared to 31.6% (n = 6) and 17.6% (n = 3) of patients treated with CBD isolates and broad-spectrum CBD products, respectively (p < 0.001). Twenty-six (74.3%) adverse events were reported by 16 patients (45.7%). The majority of these were mild (n = 12; 34.2%) and moderate (n = 10; 28.6%). Conclusion The results of this study demonstrate a positive signal of improved seizure frequency in children treated with Cannabis-based medicinal products (CBMPs) for TRE. Moreover, the results suggest that CBMPs are well-tolerated in the short term. The limitations mean causation cannot be determined in this open-label, case series. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Applying the B technologies to CICS

Author

Hoare, Jonathan, Dick, Jeremy, Neilson, Dave, Sørensen, Ib, Goos, Gerhard, editor, Hartmanis, Juris, editor, van Leeuwen, Jan, editor, Gaudel, Marie-Claude, editor, and Woodcock, James, editor

Published
1996
Full Text
View/download PDF

27. An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry

Author

Ergisi, Mehmet, primary, Erridge, Simon, additional, Harris, Michael, additional, Kawka, Michal, additional, Nimalan, Devaki, additional, Salazar, Oliver, additional, Loupasaki, Katerina, additional, Ali, Rayyan, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Beri, Sushil, additional, Hoare, Jonathan, additional, Khan, Shaheen A., additional, Weatherall, Mark W., additional, Platt, Michael, additional, Rucker, James J., additional, and Sodergren, Mikael H., additional

Published
2022
Full Text
View/download PDF

28. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

Author

Harris, Michael, primary, Erridge, Simon, additional, Ergisi, Mehmet, additional, Nimalan, Devaki, additional, Kawka, Michal, additional, Salazar, Oliver, additional, Ali, Rayyan, additional, Loupasaki, Katerina, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Hoare, Jonathan, additional, Rucker, James J, additional, Platt, Michael, additional, and Sodergren, Mikael H, additional

Published
2021
Full Text
View/download PDF

30. The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.

Author

Dalavaye, Nishaanth, Erridge, Simon, Nicholas, Martha, Pillai, Manaswini, Bapir, Lara, Holvey, Carl, Coomber, Ross, Rucker, James J, Hoare, Jonathan, and Sodergren, Mikael H

Subjects
INFLAMMATORY bowel diseases, MEDICAL marijuana, CROHN'S disease, MEDICAL registries, ULCERATIVE colitis
Abstract

Cannabis-based medicinal products (CBMPs) have shown promising preclinical activity in inflammatory bowel disease (IBD). However, clinical trials have not demonstrated effects on inflammation. This study aims to analyze changes in health-related quality of life (HRQoL) and adverse events in IBD patients prescribed CBMPs. A case series from the UK Medical Cannabis Registry was performed. Primary outcomes included changes from baseline in the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), Generalized Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L Index score at 1 and 3 months. Statistical significance was defined using p < 0.050. Seventy-six patients with Crohn's disease (n = 51; 67.11%) and ulcerative colitis (n = 25; 32.89%) were included. The median baseline SIBDQ score improved at 1 and 3 months. EQ-5D-5L index values, GAD-7, and SQS also improved after 3 months (p < 0.050). Sixteen (21.05%) patients reported adverse events with the majority being classified as mild to moderate in severity. Patients treated with CBMPs for refractory symptoms of Crohn's disease and ulcerative colitis demonstrated a short-term improvement in IBD-specific and general HRQoL. Prior cannabis consumers reported greater improvement compared to cannabis-naïve individuals. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. 850 OBJECTIVE IDENTIFICATION OF OESOPHAGEAL ADENOCARCINOMA USING MASS SPECTROMETRY IMAGING

Author

Antonowicz, Stefan, primary, Nima, Abbassi-Ghadi, additional, McKenzie, James, additional, Kumar, Sacheen, additional, Huang, Juzheng, additional, Jones, Emrys, additional, Strittmatter, Nicole, additional, Pitts, Gemma, additional, Kudo, Hiromi, additional, Goldin, Rob, additional, Hoare, Jonathan, additional, Veselkov, Kirill, additional, Takats, Zoltan, additional, and Hanna, George, additional

Published
2021
Full Text
View/download PDF

34. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, Al-Kaabi, Ali, Schoon, Erik J, Deprez, Pierre H, Seewald, Stefan, Groth, Stefan, Giovannini, Marc, Braden, Barbara, Berr, Frieder, Lemmers, Arnaud, Hoare, Jonathan, Bhandari, Pradeep, van der Post, Rachel S, Verhoeven, Rob H A, Siersema, Peter D, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, Al-Kaabi, Ali, Schoon, Erik J, Deprez, Pierre H, Seewald, Stefan, Groth, Stefan, Giovannini, Marc, Braden, Barbara, Berr, Frieder, Lemmers, Arnaud, Hoare, Jonathan, Bhandari, Pradeep, van der Post, Rachel S, Verhoeven, Rob H A, and Siersema, Peter D

Abstract

Definitive chemoradiotherapy (CRT) is increasingly used as a nonsurgical treatment for esophageal cancer. In Japanese studies, salvage endoscopic resection (ER) has emerged as a promising strategy for local failure after definitive CRT. We aimed to evaluate the safety and efficacy of salvage ER in a Western setting. Gastroenterologists from Europe and the United States were invited to submit their experience with salvage endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) after definitive CRT. Participating gastroenterologists completed an anonymized database, including patient demographics, clinicopathologic variables, and follow-up on survival and recurrence. Gastroenterologists from 10 endoscopic units in 6 European countries submitted information on 25 patients. A total of 35 salvage ER procedures were performed, of which 69% were ESD and 31% EMR. Most patients had squamous cell carcinoma (64%) of the middle or lower esophagus (68%) staged as cT2-3 (68%) and cN+ (52%) before definitive CRT. The median time from end of definitive CRT to ER was 22 months (interquartile range, 6-47). The en-bloc resection rate was 92% for ESD and 46% for EMR. During a median of 24 months (interquartile range, 12-59) of follow-up after salvage ER, 52% developed a recurrence (11 locoregional, 2 distant). The 5-year recurrence-free survival, overall survival, and disease-specific survival were 36%, 52%, and 79%, respectively. No major intra- or postprocedural adverse events, such as bleeding or perforation, were reported. In carefully selected esophageal cancer patients, salvage ER is technically feasible after definitive CRT. Further prospective research is recommended to validate the safety and effectivity of salvage ER for the management of local failure.

Published
2021

36. An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients

Author

Erridge, Simon, primary, Salazar, Oliver, additional, Kawka, Michal, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Beri, Sushil, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Weatherall, Mark W., additional, Platt, Michael, additional, Rucker, James J., additional, and Sodergren, Mikael H., additional

Published
2021
Full Text
View/download PDF

37. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience

Author

Al-Kaabi, Ali, primary, Schoon, Erik J., additional, Deprez, Pierre H., additional, Seewald, Stefan, additional, Groth, Stefan, additional, Giovannini, Marc, additional, Braden, Barbara, additional, Berr, Frieder, additional, Lemmers, Arnaud, additional, Hoare, Jonathan, additional, Bhandari, Pradeep, additional, van der Post, Rachel S., additional, Verhoeven, Rob H.A., additional, and Siersema, Peter D., additional

Published
2021
Full Text
View/download PDF

38. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience

Author

Al-Kaabi, Ali, Schoon, Erik, Deprez, Pierre, Seewald, Stefan, Groth, Stefan, Giovannini, Marc, Braden, Barbara, Berr, Frieder, Lemmers, Arnaud, Hoare, Jonathan, Bhandari, Pradeep, van der Post, Rachel R.S., Verhoeven, R.H.A., Siersema, Peter D, Al-Kaabi, Ali, Schoon, Erik, Deprez, Pierre, Seewald, Stefan, Groth, Stefan, Giovannini, Marc, Braden, Barbara, Berr, Frieder, Lemmers, Arnaud, Hoare, Jonathan, Bhandari, Pradeep, van der Post, Rachel R.S., Verhoeven, R.H.A., and Siersema, Peter D

Abstract

Background and Aims: Definitive chemoradiotherapy (CRT) is increasingly used as a nonsurgical treatment for esophageal cancer. In Japanese studies, salvage endoscopic resection (ER) has emerged as a promising strategy for local failure after definitive CRT. We aimed to evaluate the safety and efficacy of salvage ER in a Western setting. Methods: Gastroenterologists from Europe and the United States were invited to submit their experience with salvage endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) after definitive CRT. Participating gastroenterologists completed an anonymized database, including patient demographics, clinicopathologic variables, and follow-up on survival and recurrence. Results: Gastroenterologists from 10 endoscopic units in 6 European countries submitted information on 25 patients. A total of 35 salvage ER procedures were performed, of which 69% were ESD and 31% EMR. Most patients had squamous cell carcinoma (64%) of the middle or lower esophagus (68%) staged as cT2-3 (68%) and cN+ (52%) before definitive CRT. The median time from end of definitive CRT to ER was 22 months (interquartile range, 6-47). The en-bloc resection rate was 92% for ESD and 46% for EMR. During a median of 24 months (interquartile range, 12-59) of follow-up after salvage ER, 52% developed a recurrence (11 locoregional, 2 distant). The 5-year recurrence-free survival, overall survival, and disease-specific survival were 36%, 52%, and 79%, respectively. No major intra- or postprocedural adverse events, such as bleeding or perforation, were reported. Conclusions: In carefully selected esophageal cancer patients, salvage ER is technically feasible after definitive CRT. Further prospective research is recommended to validate the safety and effectivity of salvage ER for the management of local failure., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2020

39. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.

Author

Harris, Michael, Erridge, Simon, Ergisi, Mehmet, Nimalan, Devaki, Kawka, Michal, Salazar, Oliver, Ali, Rayyan, Loupasaki, Katerina, Holvey, Carl, Coomber, Ross, Usmani, Azfer, Sajad, Mohammed, Hoare, Jonathan, Rucker, James J, Platt, Michael, and Sodergren, Mikael H

Subjects
CHRONIC pain, MEDICAL marijuana, PAIN management, CHRONIC diseases, MEDICAL registries, BRIEF Pain Inventory
Abstract

To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs). A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050. 190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0–442.0mg) and 20.0mg (range:0.0–188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5 L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event. An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Learning curves and the influence of procedural volume for the treatment of dysplastic Barrett’s esophagus

Author

Lipman, Gideon, primary, Markar, Sheraz, additional, Gupta, Abhinav, additional, Haidry, Rehan J., additional, Lovat, Laurence B., additional, Novelli, Marco, additional, Banks, Matthew, additional, Sehgal, Vinay, additional, Graham, David, additional, Sweis, Rami, additional, Morris, Danielle, additional, Miah, Haroon, additional, Dunn, Jason M., additional, Smart, Howard L., additional, Bhandari, Pradeep, additional, Smith, Lesley, additional, Willert, Robert, additional, Fullarton, Grant, additional, Morris, John, additional, Di Pietro, Massimiliano, additional, Gordon, Charles, additional, Penman, Ian, additional, Barr, Hugh, additional, Patel, Praful, additional, Boger, Philip, additional, Kapoor, Neil, additional, Hoare, Jonathan, additional, Direkze, Natalie, additional, Ang, Yeng, additional, Veitch, Andrew, additional, Ragunath, Krish, additional, Cheong, Edward, additional, Dhar, Anjan, additional, Nylander, David, additional, Mahon, Brinder, additional, Narayanasamy, Ravi, additional, and O’Toole, Dermot, additional

Published
2020
Full Text
View/download PDF

44. De Novo Lipogenesis Alters the Phospholipidome of Esophageal Adenocarcinoma

Author

Abbassi-Ghadi, Nima, primary, Antonowicz, Stefan S., additional, McKenzie, James S., additional, Kumar, Sacheen, additional, Huang, Juzheng, additional, Jones, Emrys A., additional, Strittmatter, Nicole, additional, Petts, Gemma, additional, Kudo, Hiromi, additional, Court, Stephen, additional, Hoare, Jonathan M., additional, Veselkov, Kirill, additional, Goldin, Robert, additional, Takáts, Zoltán, additional, and Hanna, George B., additional

Published
2020
Full Text
View/download PDF

50. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology

Author

Oakland, Kathryn, primary, Chadwick, Georgina, additional, East, James E, additional, Guy, Richard, additional, Humphries, Adam, additional, Jairath, Vipul, additional, McPherson, Simon, additional, Metzner, Magdalena, additional, Morris, A John, additional, Murphy, Mike F, additional, Tham, Tony, additional, Uberoi, Raman, additional, Veitch, Andrew McCulloch, additional, Wheeler, James, additional, Regan, Cuthbert, additional, and Hoare, Jonathan, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results